Factor Bioscience Inc., a biotechnology company based in Cambridge, Massachusetts, has strengthened its translational science team with the addition of three members. Led by Kyle Garland, Ph.D., the team will focus on developing advanced mRNA and cell-engineering technologies. Dr. Garland, along with two Associate Scientists, Raven Hinkel and Elizabeth Belcher, brings deep expertise in translational research related to mRNA and cell engineering.
Dr. Garland and his team have experience in various scientific fields, including synthetic mRNA, cell reprogramming, gene editing, cell manufacturing, immunoengineering, and nucleic acid formulation. This diverse background will contribute to Factor’s efforts in advancing biotechnology research and development in new and innovative ways. Dr. Garland is confident in Factor’s portfolio of foundational technologies and believes they have the potential to revolutionize biotechnology research and development.
Prior to joining Factor Bioscience, Dr. Garland served as the head of Research and Development at Eterna Therapeutics, where he managed preclinical programs and strategic collaborations. He holds a Ph.D. in Chemical Engineering from Vanderbilt University and a Bachelor of Science in Bioengineering from Lehigh University.
Factor Bioscience is dedicated to developing technologies for cell engineering to improve health and quality of life. For more information about Factor Bioscience, visit www.factorbio.com
